Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring Roger K. VerbeeckGunar GüntherTim W. Rennie Review 15 June 2016 Pages: 905 - 916
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization Thomas H. LangenickelPierre JordaanIris Rajman Clinical Trial Open access 16 April 2016 Pages: 917 - 924
No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects J. HuguetJ. LuJ. Turgeon Clinical Trial 05 May 2016 Pages: 925 - 931
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis Anyue YinDewei ShangWei Lu Pharmacokinetics and Disposition 27 April 2016 Pages: 933 - 944
Pharmacokinetics study of mazindol in plasma, oral fluid, and urine of volunteers Marcella Herbstrith de OliveiraPâmela Cristina Lukasewicz FerreiraPedro Eduardo Fröehlich Pharmacokinetics and Disposition 12 April 2016 Pages: 945 - 951
Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients Kim VanstraelenJuergen PrattesIsabel Spriet Pharmacokinetics and Disposition 11 April 2016 Pages: 953 - 963
How to best assess quality of drug treatment in patients with heart failure Ramin ZarrinkoubThomas KahanBjörn Wettermark Pharmacoepidemiology and Prescription 11 April 2016 Pages: 965 - 975
Persistent analgesic use and the association with chronic pain and other risk factors in the population—a longitudinal study from the Tromsø Study and the Norwegian Prescription Database Per-Jostein SamuelsenKristian SvendsenAnne Elise Eggen Pharmacoepidemiology and Prescription 12 April 2016 Pages: 977 - 985
Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013 Maria GustafssonUlf IsakssonHugo Lövheim Pharmacoepidemiology and Prescription 13 April 2016 Pages: 987 - 994
Pro re nata (as needed) medication in nursing homes: the longer you stay, the more you get? Michael DörksGuido SchmiemannFalk Hoffmann Pharmacoepidemiology and Prescription 14 April 2016 Pages: 995 - 1001
Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score Kazuhiko NakaharaiYohei SakamotoNatsuo Tachikawa Pharmacoepidemiology and Prescription 28 April 2016 Pages: 1003 - 1011
Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors Phyo T. HtooJohn B. BuseTil Stürmer Pharmacoepidemiology and Prescription 10 May 2016 Pages: 1013 - 1023
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study Damiano PaolicelliA. ManniM. Trojano Pharmacoepidemiology and Prescription 01 June 2016 Pages: 1025 - 1029
Carbamazepine and oxcarbazepine: reflections after an oxcarbazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap Jamil Poletti-JabbourAndrés Wiegering-RospigliosiCarmen Cecilia Elías-Barrera Letter to the Editor 29 April 2016 Pages: 1031 - 1032